BioSpace News Archive

Amarin Corporation plc, announced financial results for the third quarter and nine months ended September 30, 2021 and provided an update on Company operations.

ITM Isotope Technologies Munich SE announced the presentation of the design of its new phase III trial, COMPOSE, with the radiopharmaceutical candidate n.c.a.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced ambitious commitments to address two of today’s greatest global crises—access to medicines and climate change—tied to its recently issued $5 billion sustainability-linked bond.

Bright Minds Biosciences today announced that The Nasdaq Stock Market LLC has approved the listing of the Company’s common stock on The Nasdaq Capital Market (“Nasdaq”).

G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the third quarter ended September 30, 2021.

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, November 10, 2021 to report its third quarter 2021 financial results and provide a corporate update.

Harvard Bioscience, Inc. announced financial results for the period ended September 30, 2021.

Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 9, 2021 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2021.

Arvinas, Inc. today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced its operational and financial results for the third quarter ended September 30, 2021.